Clinical Trial

Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 1, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
To study induction therapy with Nab-paclitaxel, Cisplatin and Pembrolizumab in patients with Locally Advanced HNSCC.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-02-28; most recent amendment 2025-06-30.
Status change: Not Yet Recruiting → Recruiting 2023-02-23
Trial Details
NCT Number NCT05272696
Lead Sponsor Guangdong Provincial People's Hospital
Conditions Head and Neck Squamous Cell Carcinoma
Enrollment 86 participants
Start Date 2022-03-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-01